Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/02/2001US6297238 3-aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinases particularly tyrosine kinases and serine/threonine kinases
10/02/2001US6297225 Treatment of highly vascular tumors
10/02/2001US6297223 Administering 5-substituted- or 5,6-dihydro-5-substituted-uracil derivative or a prodrug thereof; in conjunction with 5-fluorouracil or pro-drug thereof.
10/02/2001US6297217 Boronic ester and acid compounds, synthesis and uses
10/02/2001US6297050 Activation of t-cell response; mix peptides with sample containing t-cells and detect bound human leukocyte antigens
10/02/2001US6297036 YAK-1 related serine/threonine protein kinase-HTLAR33
10/02/2001US6297022 Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
10/02/2001US6297003 Methods for the detection of a novel hepatitis C virus (HCV) terminal 3′ noncoding region
10/02/2001US6296853 For therapy of animal having a papilloma viral infection
10/02/2001US6296850 Apoptosis-related compounds and their use
10/02/2001US6296845 Contacting under infective conditions, a recombinant replication deficient adenovirus lacking an expressed viral oncoprotein capable of binding functional p53 tumor suppressor gene product, with neoplastic cellsnon-neoplastic cells
10/02/2001US6296843 Mutagenized IL 13-based chimeric molecules
10/02/2001US6296831 Biodegradation; in cancer tumor therapy
10/02/2001CA2250092C Triaryl and diaryl compounds, their analogues and uses thereof
10/02/2001CA2078000C Neutrophil stimulating peptides
09/2001
09/27/2001WO2001071358A1 Method of screening for inhibitors of osteopontin
09/27/2001WO2001071309A2 Methods and reagents for regulation of cellular responses in biological systems
09/27/2001WO2001071022A2 Lpa receptor agonists and antagonists and methods of use
09/27/2001WO2001071015A2 Non-squamous epithelium-specific transcription
09/27/2001WO2001071007A2 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
09/27/2001WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
09/27/2001WO2001071004A2 Proteases
09/27/2001WO2001070985A2 Bi-functional cancer treatment agents
09/27/2001WO2001070984A2 Anti-tissue factor antibodies with enhanced anticoagulant potency
09/27/2001WO2001070982A2 Brca-1 regulators and methods of use
09/27/2001WO2001070979A2 Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
09/27/2001WO2001070978A2 Polypeptides and nucleic acids encoding same
09/27/2001WO2001070974A1 Novel protein, process for producing the same and use thereof
09/27/2001WO2001070950A2 Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion
09/27/2001WO2001070945A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments
09/27/2001WO2001070941A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
09/27/2001WO2001070938A1 Detection of immunological memory, t-cell conjugates for pathology imaging and therapy
09/27/2001WO2001070808A2 Angiogenesis - associated proteins, and nucleic acids encoding the same
09/27/2001WO2001070807A2 G-protein associated molecules
09/27/2001WO2001070804A1 7 human ovarian and ovarian cancer associated proteins
09/27/2001WO2001070798A2 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent
09/27/2001WO2001070784A1 A novel polypeptide-human protein 17 containing chromo domain and the polynucleotide encoding said polypeptide
09/27/2001WO2001070783A1 A novel polypeptide-human gamma-cop protein 16 and the polynucleoide encoding said polypeptide
09/27/2001WO2001070781A1 A novel polypeptide-human ilf 13 and the polynucleotide encoding said polypeptide
09/27/2001WO2001070780A1 A novel polypeptide-human ribosomal sii protein 12 and the polynucleotide encoding said polypeptide
09/27/2001WO2001070775A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
09/27/2001WO2001070772A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid
09/27/2001WO2001070767A2 Therapeutic anti-melanoma compounds
09/27/2001WO2001070766A2 Therapeutic anti-cytomegalovirus compounds
09/27/2001WO2001070757A2 Thioketals and thioethers for inhibiting the expression of vcam-1
09/27/2001WO2001070755A1 Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents
09/27/2001WO2001070754A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
09/27/2001WO2001070753A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
09/27/2001WO2001070747A1 Process for producing camptothecin
09/27/2001WO2001070742A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
09/27/2001WO2001070741A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
09/27/2001WO2001070738A2 Tri-aryl-substituted-ethane pde4 inhibitors
09/27/2001WO2001070734A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
09/27/2001WO2001070729A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
09/27/2001WO2001070723A1 Benzothiophene derivatives and medicinal use thereof
09/27/2001WO2001070720A2 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
09/27/2001WO2001070718A1 Taxane anticancer agents
09/27/2001WO2001070716A1 A process for the preparation of epothilone analogs and intermediates
09/27/2001WO2001070696A1 Nitroethenamine derivatives or salts thereof and pharmaceutical compositions containing the derivatives or the salts
09/27/2001WO2001070695A1 Pyridine derivatives as inhibitors of p38
09/27/2001WO2001070694A1 Amorphous torasemide modification
09/27/2001WO2001070693A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors
09/27/2001WO2001070691A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
09/27/2001WO2001070690A1 Heterocyclic side chain containing metalloprotease inhibitors
09/27/2001WO2001070682A2 Carbocyclic side chain containing metalloprotease inhibitors
09/27/2001WO2001070676A1 Sponge antitumor compounds
09/27/2001WO2001070675A2 Inhibitors of histone deacetylase
09/27/2001WO2001070673A2 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a)
09/27/2001WO2001070668A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
09/27/2001WO2001070663A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
09/27/2001WO2001070662A2 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
09/27/2001WO2001070275A2 Polyglutamic acid-camptothecin conjugates and methods of preparation
09/27/2001WO2001070268A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
09/27/2001WO2001070255A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
09/27/2001WO2001070254A1 Use of human not1 and not1a orphan receptors
09/27/2001WO2001070251A1 Anticancer compositions
09/27/2001WO2001070249A1 Cosmetic use of hop and ornithine
09/27/2001WO2001070244A1 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
09/27/2001WO2001070233A2 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
09/27/2001WO2001070219A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
09/27/2001WO2001070208A2 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
09/27/2001WO2001070199A1 Matrices containing nitric oxide donors and reducing agents and their use
09/27/2001WO2001070175A2 Osteocalcin promoter directed adenovirus replicaton for therapy
09/27/2001WO2001070174A2 Vegf-modulated genes and methods employing them
09/27/2001WO2001070095A2 Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
09/27/2001WO2001070093A2 Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
09/27/2001WO2001062234A8 Dosing regimen
09/27/2001WO2001032663A3 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
09/27/2001WO2001021207A3 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
09/27/2001WO2001019829A3 Pyrazolopyrimidines as therapeutic agents
09/27/2001WO2001019824A3 New active marine alkaloids
09/27/2001WO2001019794A3 Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
09/27/2001WO2001019320A3 Phospholipid prodrugs of anti-proliferative drugs
09/27/2001WO2001017551A3 Combined vaccine compositions
09/27/2001WO2001016296A3 Use of cytokines, cells, and mitogens to inhibit graft versus host disease
09/27/2001WO2001016170A3 Card proteins involved in cell death regulation
09/27/2001WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity
09/27/2001WO2001009178A3 Human chaperone proteins
09/27/2001WO2000071148A3 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
09/27/2001WO2000041707A3 USE OF $i(LACTOBACILLUS SALIVARIUS)